Published in Drug Resist Updat on September 28, 2015
Regulators of mitochondrial dynamics in cancer. Curr Opin Cell Biol (2016) 0.87
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet (1996) 12.96
SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell (1996) 11.22
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol (1999) 9.92
RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell (2007) 9.25
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev (1999) 6.56
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell (2003) 5.72
Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J (2000) 5.61
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet (2014) 3.90
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Substrate targeting in the ubiquitin system. Cell (1999) 3.51
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (1987) 3.46
BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev (2006) 3.44
Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature (2014) 3.36
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A (1998) 3.26
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol (2000) 3.07
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet (2001) 2.98
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature (2008) 2.84
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
MicroRNA biogenesis pathways in cancer. Nat Rev Cancer (2015) 2.67
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem (2003) 2.59
Inherited susceptibility to common cancers. N Engl J Med (2008) 2.54
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet (1987) 2.48
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A (2003) 2.45
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol (2004) 2.45
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 2.35
JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev (1998) 2.29
Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J (2002) 2.19
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science (2011) 2.17
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst (1994) 2.06
MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle (2011) 2.06
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology (2002) 2.05
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet (2010) 2.03
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet (2014) 2.01
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A (1998) 2.00
Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene (1996) 2.00
Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med (2007) 1.99
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res (2002) 1.89
The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res (1998) 1.88
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res (2007) 1.85
Integrated genomic characterization of adrenocortical carcinoma. Nat Genet (2014) 1.81
Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J Biol Chem (2004) 1.74
F-box protein Skp2: a novel transcriptional target of E2F. Oncogene (2006) 1.74
VHL, the story of a tumour suppressor gene. Nat Rev Cancer (2015) 1.71
Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell (2015) 1.70
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res (2009) 1.64
MDM2 and prognosis. Mol Cancer Res (2004) 1.62
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med (2011) 1.62
Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol (2008) 1.60
Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res (2003) 1.60
RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet (2014) 1.57
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev (2003) 1.56